Source: BioSpace
Area: News
Ophthotech Corporation has announced results from a prospective, randomised, controlled phase IIb trial of FovistaTM and ranibizumab combination therapy that show statistically significant superior efficacy over ranibizumab monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).
Fovista, formerly known as E10030, is an aptamer directed against platelet-derived growth factor subunit B (PDGF-B), which regulates neovascular pericytes (cells associated with the walls of newly formed small blood vessels).
In the study, 449 patients were randomised to receive one of the following treatment regimens administered every four weeks for 24 weeks: Fovista 0.3 mg in combination with ranibizumab 0.5 mg; Fovista 1.5 mg in combination with ranibizumab 0.5 mg; or sham in combination with Lucentis 0.5 mg. The primary efficacy endpoint in the study was the mean change in visual acuity from baseline at the week 24 visit. Patients ...
Uncategorized